Cargando…

Outcome of Allogeneic Stem Cell Transplantation Following Reduced-Intensity Conditioninig Regimen in Patients With Idiopathic Myelofibrosis: the G.I.T.M.O. Experience

BACKGROUND: Allogeneic stem cell transplantation (SCT) is a potentially curative treatment for myelofibrosis (MI), though limited by a high rate of transplant-related mortality (TRM). In the present study we evaluate the outcome of MI patients undergoing an allogenic SCT after reduced intensity cond...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patriarca, Francesca, Bacigalupo, Andrea, Sperotto, Alessandra, Isola, Miriam, Bruno, Barbara, van Lint, Maria Teresa, Iori, Anna Paola, Di Bartolomeo, Paolo, Musso, Maurizio, Pioltelli, Pietro, Visani, Giuseppe, Iacopino, Pasquale, Fanin, Renato, Bosi., Alberto
Formato:	Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2010
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033132/ https://www.ncbi.nlm.nih.gov/pubmed/21415963 http://dx.doi.org/10.4084/MJHID.2010.010

Ejemplares similares

Donor Lymphocyte Infusions After Allogeneic Stem Cell Transplantation in Acute Leukemia: A Survey From the Gruppo Italiano Trapianto Midollo Osseo (GITMO)
por: Patriarca, Francesca, et al.
Publicado: (2020)

P1539: INFECTION-RELATED MORTALITY CLINICAL-BIOLOGICAL SCORING SYSTEM (IRM-SCORE) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A VALIDATION STUDY IN GITMO CENTRES
por: Clerici, Daniela, et al.
Publicado: (2023)

Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021
por: Bacigalupo, Andrea, et al.
Publicado: (2021)

Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome
por: Alessandrino, Emilio Paolo, et al.
Publicado: (2013)

Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study
por: Malagola, Michele, et al.
Publicado: (2023)

Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis
por: Murthy, Guru Subramanian Guru, et al.
Publicado: (2023)

2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management
por: Ali, Haris, et al.
Publicado: (2021)

Is Allogeneic Transplantation an Option in Patients Affected by Concurrent Myelofibrosis and Chronic Myeloid Leukemia (CML)?
por: Sora, Federica, et al.
Publicado: (2021)

Predicting the outcome for patients with myelofibrosis undergoing an allogeneic hemopoietic stem cell transplant
por: Sora, Federica, et al.
Publicado: (2022)

Donor cell-derived myelofibrosis relapse after allogeneic stem cell transplantation
por: Chiusolo, Patrizia, et al.
Publicado: (2022)

Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01
por: Bonifazi, Francesca, et al.
Publicado: (2022)

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
por: Robin, Marie, et al.
Publicado: (2019)

Allogeneic hematopoietic stem-cell transplantation for myelofibrosis
por: Zhang, Lining, et al.
Publicado: (2020)

P50 OVERALL SURVIVAL ADVANTAGE OF MONOCLONAL ANTIBODIES BASED-TREATMENTS IN MULTIPLE MYELOMA PATIENTS RELAPSED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
por: Nozzoli, C., et al.
Publicado: (2023)

Iron Chelation Therapy with Deferasirox in the Management of Iron Overload in Primary Myelofibrosis
por: Elli, Elena Maria, et al.
Publicado: (2014)

Microbial monitoring and methods of sample collection: a GITMO survey (Gruppo Trapianto di Midollo Osseo)
por: Gori, Erica, et al.
Publicado: (2014)

Veno-occlusive disease nurse management: development of a dynamic monitoring tool by the GITMO nursing group
por: Botti, Stefano, et al.
Publicado: (2016)

Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis
por: Helbig, Grzegorz, et al.
Publicado: (2019)

The Use of Allogeneic Hematopoietic Stem Cell Transplantation in Primary Myelofibrosis
por: Wolfe, Heather R., et al.
Publicado: (2022)

Risk Factors and Outcome of C. difficile Infection after Hematopoietic Stem Cell Transplantation
por: Rosignoli, Chiara, et al.
Publicado: (2020)

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
por: McLornan, Donal P., et al.
Publicado: (2019)

How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation
por: Polverelli, Nicola, et al.
Publicado: (2022)

Treosulfan-Based Conditioning Regimen for Second Allograft in Patients with Myelofibrosis
por: Atagunduz, Isik Kaygusuz, et al.
Publicado: (2020)

Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation
por: Srour, Samer A., et al.
Publicado: (2019)

Allogeneic stem cell transplant for myelofibrosis- A retrospective single-center study
por: Choudhary, Dharma, et al.
Publicado: (2023)

How I manage anemia related to myelofibrosis and its treatment regimens
por: Verstovsek, Srdan
Publicado: (2023)

Use of Next Generation Sequencing to Define the Origin of Primary Myelofibrosis
por: Visani, Giuseppe, et al.
Publicado: (2023)

Gamma-Delta T-Cell Lymphoma Following Allogeneic Stem Cell Transplant for Primary Myelofibrosis
por: Hoard, Robert, et al.
Publicado: (2020)

Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial
por: Bruna, Riccardo, et al.
Publicado: (2019)

Experiences of allogeneic hematopoietic cell transplantation following non-myeloablative conditioning regimen in severely comorbid patients with myelofibrosis: case series with a patient presenting with extensive extramedullary hematopoiesis
por: Yoon, Jae-Ho, et al.
Publicado: (2020)

Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT
por: Kröger, Nicolaus, et al.
Publicado: (2021)

Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCT
por: Murata, M, et al.
Publicado: (2014)

Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis
por: Murata, Makoto, et al.
Publicado: (2020)

Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups
por: Robin, Marie, et al.
Publicado: (2021)

Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome
por: Zeng, Xiangzong, et al.
Publicado: (2021)

Reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for patients with myelofibrosis
por: Kim, Dong Hyun, et al.
Publicado: (2022)

Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide
por: Trunk, Andrew D., et al.
Publicado: (2023)

Myelofibrosis
por: Passamonti, Francesco, et al.
Publicado: (2023)

Nutritional support in patients undergoing haematopoietic stem cell transplantation: a multicentre survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programmes
por: Botti, Stefano, et al.
Publicado: (2015)

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_r56t3l147mdg5ja4mpp6cuond8